Evidence map›Paper›PMID 31995767›Full record

ArticleCell reports2020

Immunological Fingerprints of Controllers Developing Neutralizing HIV-1 Antibodies.

Enrique Martin-Gayo, Ce Gao, Hsiao Rong Chen, Zhengyu Ouyang, Dhohyung Kim, Kellie E Kolb, Alex K Shalek, Bruce D Walker, Mathias Lichterfeld, Xu G Yu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 26 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Enrique Martin-GayoRagon Institute of MGH, MIT, and Harvard, Boston, MA, USA; Universidad Autónoma de Madrid, Hospital de la Princesa, Madrid, Spain. Electronic address: enrique.martin@uam.es.
Ce GaoRagon Institute of MGH, MIT, and Harvard, Boston, MA, USA.
Hsiao Rong ChenRagon Institute of MGH, MIT, and Harvard, Boston, MA, USA.
Zhengyu OuyangRagon Institute of MGH, MIT, and Harvard, Boston, MA, USA.
Dhohyung KimRagon Institute of MGH, MIT, and Harvard, Boston, MA, USA.
Kellie E KolbRagon Institute of MGH, MIT, and Harvard, Boston, MA, USA; Department of Chemistry, MIT Institute for Medical Engineering and Science (IMES), MIT, Cambridge, MA, USA; Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Alex K ShalekRagon Institute of MGH, MIT, and Harvard, Boston, MA, USA; Department of Chemistry, MIT Institute for Medical Engineering and Science (IMES), MIT, Cambridge, MA, USA; Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Bruce D WalkerRagon Institute of MGH, MIT, and Harvard, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Howard Hughes Medical Institute, Chevy Chase, MD, USA.
Mathias LichterfeldRagon Institute of MGH, MIT, and Harvard, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Infectious Disease Division, Brigham and Women's Hospital, Boston, MA, USA; Infectious Disease Division, Massachusetts General Hospital, Boston, MA, USA.
Xu G YuRagon Institute of MGH, MIT, and Harvard, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Infectious Disease Division, Brigham and Women's Hospital, Boston, MA, USA; Infectious Disease Division, Massachusetts General Hospital, Boston, MA, USA. Electronic address: xyu@mgh.harvard.edu.
Ragon Institute of MGH, MIT and Harvard · USBroad Institute · USAllen Institute · USHoward Hughes Medical Institute · USUniversidad Autónoma de Madrid · ES

Funding

Role of Negative Costimulation in Regulation of AutoimmunityP01AI039671 · NIAID · YALE UNIVERSITY · PI David A. Hafler · 1996 to 2026
$51.7M
Systems investigation of vaccine responses in B cell depleted autoimmune patientsU19AI089992 · NIAID · YALE UNIVERSITY · PI David A. Hafler, RUTH R MONTGOMERY · 2010 to 2026
$50.4M
Center for Cell CircuitsRM1HG006193 · NHGRI · BROAD INSTITUTE, INC. · PI BLAINEY, PAUL CLARK, HACOHEN, NIR · 2016 to 2020
$14.9M
The Cellular Geography of Therapeutic Resistance in CancerU2CCA233195 · NCI · DANA-FARBER CANCER INST · PI JOHNSON, BRUCE E. · 2018 to 2023
$13.7M
Novel Biologic Therapies for GVHDR01HL095791 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI KEAN, LESLIE S · 2010 to 2025
$13.3M
Quantitative and functional characterization of therapeutic resistance in cancerU54CA217377 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LAUFFENBURGER, DOUGLAS A, MANALIS, SCOTT R · 2017 to 2021
$10.2M
Immunoregulatory Function of Myelomonocytic Receptors in HIV-1 InfectionR01AI078799 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI YU, XU · 2008 to 2017
$4.1M
Molecular profile of proviral reservoirs in HIV-infected drug usersR61DA047034 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI LICHTERFELD, MATHIAS, YU, XU · 2018 to 2020
$3.4M
A systems biology approach to fingerprint HIV immune defense in Elite ControllersR01HL134539 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI YU, XU · 2016 to 2019
$3.3M
T cells in HCV/HIV co-infectionR01DA046277 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI LAUER, GEORG MICHAEL · 2018 to 2022
$3.2M
An integrated multiplexed genomic assay for low input clinical samples1U24AI118672 · NIAID · BROAD INSTITUTE, INC. · PI SHALEK, ALEX K · 2015 to 2019
$2.0M
Molecular profile of proviral reservoirs in HIV-infected drug usersR33DA047034 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI LICHTERFELD, MATHIAS, YU, XU · 2022 to 2024
$2.0M
NCI NIH HHS R33 CA202820NCI NIH HHS U2C CA233195NCI NIH HHS U54 CA217377NHGRI NIH HHS RM1 HG006193NHLBI NIH HHS R01 HL095791NHLBI NIH HHS R01 HL134539NIAID NIH HHS P01 AI039671NIAID NIH HHS R01 AI078799NIAID NIH HHS R01 AI138546NIAID NIH HHS R21 AI116228NIAID NIH HHS R21 AI140930NIAID NIH HHS R33 AI116228NIAID NIH HHS R56 AI125109NIAID NIH HHS U19 AI089992NIAID NIH HHS U24 AI118672NIDA NIH HHS R01 DA046277NIDA NIH HHS R33 DA047034NIDA NIH HHS R61 DA047034
6 · The paper itself

Abstract

The induction of broadly neutralizing antibodies (bnAbs) is highly desired for an effective vaccine against HIV-1. Typically, bnAbs develop in patients with high viremia, but they can also evolve in some untreated HIV-1 controllers with low viral loads. Here, we identify a subgroup of neutralizer-controllers characterized by myeloid DCs (mDCs) with a distinct inflammatory signature and a superior ability to prime T follicular helper (Tfh)-like cells in an STAT4-dependent fashion. This distinct immune profile is associated with a higher frequency of Tfh-like cells in peripheral blood (pTfh) and an enrichment for Tfh-defining genes in circulating CD4

Indexed as

AdultAgedAntibodies, NeutralizingB-LymphocytesCD4-Positive T-LymphocytesCell LineCell SurvivalDendritic CellsFemaleGene Expression RegulationHIV-1HIV AntibodiesHIV InfectionsHumansInterleukin-12MaleAntibodies, NeutralizingHIV AntibodiesInterleukin-12STAT4 protein, humanSTAT4 Transcription FactorB cellbnAbCD4 T cellcontrollerdendritic cellHIVmonocyteneutralizerRNAseqsystems biology

Identifiers

PMID31995767
PMCPMC6990401
OpenAlexW3003476369

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.